Market research
TSTL.LSE Tristel plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 206M
- P/E ratio
- 26.72
- Analyst target
- 475.181
- Dividend yield
- 3.3%
- Beta
- 0.35
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- GB00B07RVT99
- Market cap
- 206M
- P/E ratio
- 26.72
- Analyst target
- 475.181
- Dividend yield
- 3.3%
- Beta
- 0.35
About
About Tristel plc
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for Stella, rinse assure, clean, EVE, medistel, EVA system, daisygrip, fuse for surfaces, dosing system, airstel, enzystel, DOK, pre-clean wipes, rinse wipes, sporicidal wipes, clean for Stella, protect, and wipes; surface disinfection products, such as FUSE, JET, JET LUX, JET PRO, TANK 10 CLO2, TANK 5 CLO2, and TILT 5 CLO2; as well as operates 3T, a cloud-based platform alternative to paper-based traceability systems. The company provides its medical disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TSTL.LSE discussion.
5 years, 5 months ago
Tristel plc is currently in a long term uptrend where the price is trading 13.2% above its 200 day moving average.
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.0.
Tristel plc's total revenue sank by 0.0% to $7M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $1M since the same quarter in the previous year.
Finally, its free cash flow grew by 50.2% to $2M since the same quarter in the previous year.
Based on the above factors, Tristel plc gets an overall score of 3/5.